FDA commissioner will discuss regulations, research, health challenges

Robert M. Califf will join Cornell leaders at a public event on Oct. 16 to discuss approaches to persistent and emerging threats to Americans’ health.

Study finds mutations, DNA structures driving bladder cancer

A study led by researchers at Weill Cornell Medicine and the New York Genome Center found that antiviral enzymes that mutate the DNA of normal and cancer cells are key promoters of early bladder cancer development.

NYC entrepreneurship conference features CEOs, NBA leader

The 2024 Eclectic Convergence conference in New York City, organized by Entrepreneurship at Cornell, is set for Nov. 15.

Around Cornell

Dr. Randy Longman receives NIH Transformative Research Award

The award funds innovative but inherently risky research endeavors that have the potential to overturn existing scientific paradigms or create new ones.

Revising Medicare Part D prescription policy could save billions

Weill Cornell Medicine researchers have found that removing protected class regulation from Medicare prescription drug policies could greatly reduce the United States' prescription drug spending, potentially saving $47 billion between 2011 and 2019.

Young adults fear their parents will read online health portals

Weill Cornell Medicine researchers found that the possibility of parental disclosure through online patient portals led older adolescents to hesitate in sharing complete health information with doctors.

Researchers gain insights into KRAS mutations in pancreatic cancers

A mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma compared with other variants, according to a multicenter study conducted at Weill Cornell Medicine, NewYork-Presbyterian and other institutions.

Alzheimer’s genetic risk factors spark inflammation in females

A new study emphasizes the importance of considering sex differences in Alzheimer’s research – a step that could ultimately lead to more precise and effective treatments.

New tool quantifies cancer’s ability to shape-shift

A powerful new analytical tool offers a closer look at how tumor cells “shape-shift” to become more aggressive and untreatable, as shown in a study from researchers at Weill Cornell Medicine and the New York Genome Center.